Back to resaerch topics Biotherapy

Oral administration is currently the most widely used route of drug delivery, due to its ease of use combined with good patient compliance. However, the routes of administration of vectorized nucleic acids are most often local or by intravenous injection. Thus, a formulation designed for oral administration of siRNA would have significant potential for the development of new therapies.

This project is being carried out in collaboration with Professor Tchoreloff’s team (CNRS UMR 5295 Bordeaux). We have shown that it is possible to formulate siRNA vectors into tablets while preserving the gene silencing efficiency of the particle, and have filed a patent describing this process. We then showed that, when administered orally to rodents with dextran sulfate-induced ulcerative colitis, siRNA vectors in compressed form were able to specifically inhibit the target gene, in this case that of the cytokine TNF-α. These results pave the way for the administration of siRNA vectors in dry form.

Brevet FR 17 54105 PCT 2018 WO2018206723A1

Read the article “les comprimés de lipoplexes de siRNA”

Back to research topics Biotherapy